CN1263745C - 芳基稠合的氮杂多环化合物 - Google Patents

芳基稠合的氮杂多环化合物 Download PDF

Info

Publication number
CN1263745C
CN1263745C CNB018055737A CN01805573A CN1263745C CN 1263745 C CN1263745 C CN 1263745C CN B018055737 A CNB018055737 A CN B018055737A CN 01805573 A CN01805573 A CN 01805573A CN 1263745 C CN1263745 C CN 1263745C
Authority
CN
China
Prior art keywords
ring
azepine
triolefin
compound
tetraene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018055737A
Other languages
English (en)
Chinese (zh)
Other versions
CN1406227A (zh
Inventor
P·R·P·布鲁克
J·W·科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1406227A publication Critical patent/CN1406227A/zh
Application granted granted Critical
Publication of CN1263745C publication Critical patent/CN1263745C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB018055737A 2000-02-25 2001-02-08 芳基稠合的氮杂多环化合物 Expired - Fee Related CN1263745C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,002 2000-02-25
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
CN1406227A CN1406227A (zh) 2003-03-26
CN1263745C true CN1263745C (zh) 2006-07-12

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018055737A Expired - Fee Related CN1263745C (zh) 2000-02-25 2001-02-08 芳基稠合的氮杂多环化合物

Country Status (39)

Country Link
US (3) US6605610B1 (enExample)
EP (2) EP1619192B1 (enExample)
JP (1) JP2003524002A (enExample)
KR (1) KR100537976B1 (enExample)
CN (1) CN1263745C (enExample)
AP (1) AP1860A (enExample)
AT (2) ATE328872T1 (enExample)
AU (2) AU784081B2 (enExample)
BG (1) BG65891B1 (enExample)
BR (1) BR0108610A (enExample)
CA (1) CA2401229C (enExample)
CR (1) CR6726A (enExample)
CU (1) CU23148A3 (enExample)
CY (1) CY1105301T1 (enExample)
CZ (1) CZ303203B6 (enExample)
DE (2) DE60140965D1 (enExample)
DK (2) DK1259489T3 (enExample)
DZ (1) DZ3328A1 (enExample)
EA (1) EA005316B1 (enExample)
EE (1) EE200200475A (enExample)
ES (2) ES2263640T3 (enExample)
GE (1) GEP20053454B (enExample)
HR (1) HRP20020700A2 (enExample)
HU (1) HU229482B1 (enExample)
IL (2) IL150639A0 (enExample)
IS (1) IS2293B (enExample)
MA (1) MA26875A1 (enExample)
MX (1) MXPA02008311A (enExample)
NO (1) NO323608B1 (enExample)
NZ (1) NZ519973A (enExample)
OA (1) OA12181A (enExample)
PL (1) PL365163A1 (enExample)
PT (1) PT1259489E (enExample)
RS (1) RS51123B (enExample)
SI (1) SI1259489T1 (enExample)
SK (1) SK12042002A3 (enExample)
UA (1) UA74813C2 (enExample)
WO (1) WO2001062736A1 (enExample)
ZA (1) ZA200206768B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136727A0 (en) * 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
JP2004527545A (ja) * 2001-04-20 2004-09-09 ファイザー・プロダクツ・インク １，３−置換インデンおよびアリール縮合アザ多環式化合物の調製方法
CA2460118A1 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
IL161857A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
BR0214578A (pt) * 2001-11-30 2004-11-03 Pfizer Prod Inc Compostos azopolicìclicos fundidos com arila
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2174714B1 (en) * 2002-10-22 2013-04-17 EMD Millipore Corporation Apparatus with a composite structure for sample preparation
RU2284319C2 (ru) * 2002-11-25 2006-09-27 Пфайзер Продактс Инк. Усовершенствованный способ получения 1,3-замещенных инденов
US20070066827A1 (en) * 2003-01-15 2007-03-22 Pfizer Inc. Process for the preparation of aryl fused polycyclic lactams
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
JP2006528170A (ja) * 2003-07-21 2006-12-14 ファイザー・プロダクツ・インク アリール縮合型アザ多環式化合物
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005037784A2 (en) * 2003-10-14 2005-04-28 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
AU2006217616A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Preparation of high purity substituted quinoxaline
AU2007242526A1 (en) * 2006-04-24 2007-11-01 Pfizer Products Inc. Asymmetric membranes for drug delivery devices
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8039620B2 (en) * 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
US8178537B2 (en) * 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
CN118324762A (zh) * 2020-01-03 2024-07-12 布鲁奥科制药有限公司 用于治疗cns病症的化合物和组合物
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
IL136727A0 (en) * 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO1999055680A1 (en) 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
CA2361525C (en) * 1999-01-29 2009-12-08 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (en) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer ASYMMETRIC SYNTHESIS OF (S, S, R) - (-) - ACTINONE AND ITS ANALOG AND USES THEREOF
JP2006528170A (ja) * 2003-07-21 2006-12-14 ファイザー・プロダクツ・インク アリール縮合型アザ多環式化合物
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
IS2293B (is) 2007-10-15
KR100537976B1 (ko) 2005-12-21
PL365163A1 (en) 2004-12-27
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
GEP20053454B (en) 2005-02-25
HUP0204580A2 (hu) 2003-04-28
EP1259489A1 (en) 2002-11-27
ES2336800T3 (es) 2010-04-16
BG106908A (bg) 2003-04-30
MXPA02008311A (es) 2002-12-09
US7144882B2 (en) 2006-12-05
US20030130260A1 (en) 2003-07-10
CZ20022778A3 (cs) 2003-09-17
HU229482B1 (en) 2014-01-28
BR0108610A (pt) 2002-11-19
OA12181A (en) 2006-05-09
EP1619192A3 (en) 2006-03-22
MA26875A1 (fr) 2004-12-20
AU2874801A (en) 2001-09-03
UA74813C2 (en) 2006-02-15
HRP20020700A2 (en) 2004-12-31
AP2002002604A0 (en) 2002-09-30
CN1406227A (zh) 2003-03-26
PT1259489E (pt) 2006-08-31
AP1860A (en) 2008-07-02
YU59602A (sh) 2005-06-10
AU784081B2 (en) 2006-02-02
ATE453643T1 (de) 2010-01-15
RS51123B (sr) 2010-10-31
EA200200716A1 (ru) 2003-02-27
IS6459A (is) 2002-07-05
JP2003524002A (ja) 2003-08-12
DK1619192T3 (da) 2010-03-29
DE60120366D1 (de) 2006-07-20
DE60120366T2 (de) 2007-07-05
IL150639A0 (en) 2003-02-12
AU2005234671A1 (en) 2005-12-15
ATE328872T1 (de) 2006-06-15
NO323608B1 (no) 2007-06-18
SK12042002A3 (sk) 2004-02-03
EP1619192A2 (en) 2006-01-25
NO20024042D0 (no) 2002-08-23
EP1619192B1 (en) 2009-12-30
CR6726A (es) 2003-10-28
CA2401229A1 (en) 2001-08-30
IL150639A (en) 2011-10-31
EP1259489B1 (en) 2006-06-07
SI1259489T1 (sl) 2006-10-31
CY1105301T1 (el) 2010-03-03
DZ3328A1 (enExample) 2001-08-30
CA2401229C (en) 2007-10-02
CU23148A3 (es) 2006-06-29
HK1050894A1 (en) 2003-07-11
EA005316B1 (ru) 2004-12-30
US7205300B2 (en) 2007-04-17
BG65891B1 (bg) 2010-04-30
CZ303203B6 (cs) 2012-05-23
HUP0204580A3 (en) 2005-04-28
WO2001062736A1 (en) 2001-08-30
US20030130261A1 (en) 2003-07-10
ZA200206768B (en) 2003-09-23
DE60140965D1 (de) 2010-02-11
EE200200475A (et) 2003-12-15
US6605610B1 (en) 2003-08-12
KR20030005209A (ko) 2003-01-17
DK1259489T3 (da) 2006-10-09
AU2005234671B2 (en) 2008-04-17
ES2263640T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
CN1263745C (zh) 芳基稠合的氮杂多环化合物
CN1715280A (zh) 芳基稠合氮杂多环化合物
CN1503781A (zh) 1,3-取代的茚类和芳基稠合的氮杂多环化合物的制备方法
CN1313450C (zh) 速激肽受体拮抗剂
CN1148357C (zh) 三唑衍生物
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1553909A (zh) 作为gaba受体配体的苯并咪唑和吡啶并咪唑衍生物
CN1639161A (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1092771A (zh) 氨基亚甲基取代的非芳香杂环化合物
CN1646502A (zh) 用作速激肽受体拮抗剂的三唑衍生物
CN1121717A (zh) 杂环化合物及其制备方法和用途
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1432011A (zh) 含有苯并酰胺哌啶的化合物及相关的化合物
CN1802187A (zh) 趋化因子受体的苯并噁嗪基－酰胺基环戊基－杂环调节剂
CN1294133C (zh) 作为gaba受体配体的咪唑并－嘧啶衍生物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1913778A (zh) 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂
CN1193966A (zh) 芳族化合物和含有它们的药物组合物
CN1473160A (zh) 抗真菌和/或抗寄生虫的药物组合物以及作为该组合物活性组分的新的吲哚衍生物
CN1805965A (zh) 趋化因子受体活性调节剂杂环基环戊基四氢异喹啉和杂环基环戊基四氢吡啶并吡啶
CN1890242A (zh) 吡唑并和咪唑并－嘧啶衍生物
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1826334A (zh) 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
CN1812992A (zh) Hiv整合酶抑制剂
CN1144787C (zh) 芳基稠合氮杂多元环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060712

Termination date: 20150208

EXPY Termination of patent right or utility model